Boehringer Ingelheim Articles
Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
17 May 2013
Surveys reveal opportunity for medical community to fully embrace biomarker testing in lung cancer
7 May 2013
Boehringer Ingelheim Venture Fund invests in Eyevensys
15 April 2013
US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018
10 April 2013
Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz
26 March 2013
FDA confirms views that Boehringer's Pradaxa bleeding rates no higher than for warfarin
19 March 2013
Pharmaco-invasive strategy including Metalyse comparable to primary PCI for STEMI patients
11 March 2013
Interim results indicate potent activity of Boehringer's faldaprevir in HCV/HIV co-infected patients
5 March 2013
Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma patients
25 February 2013
Positive trials results for Boehringer Ingelheim's Pradaxa for prevention of recurrent DVT and PE
22 February 2013
FDA advisory panel backs Boehringer's COPD drug olodaterol
30 January 2013
SOBI gains EMA approval for change of Kineret producer; Novartis drops NIC002 project
23 January 2013
Boehringer Ingelheim's afatinib NDA gets priority review in USA
16 January 2013
Drug discovery alliances for Boehringer and Horizon Discovery; and NovAliX with Kyowa Hakko
15 January 2013
Lilly and Boehringer adjust LY2605541 deal; announce positive Ph III data for empagliflozin
8 January 2013
Brazil's atrial fibrillation market to grow at 31% annually over the next five years
19 December 2012
Australian review finds more work needed on new anticoagulants
19 December 2012
Once again, no proof of added benefit found for Boehringer/Lilly's Trajenta by Germany's IQWiG
13 December 2012
Forest launches COPD product Tudorza in USA
12 December 2012
Study attacks Pharma business practices in Brazil
11 December 2012
Boehringer Ingelheim partners on DARPin molecules
12 November 2012
Boehringer Ingelheim highlights robust respiratory R&D pipeline; announces investment
1 November 2012
Boehringer Ingelheim to pay $95 million to resolve False Claims Act allegations in USA
29 October 2012
New LABA/LAMA drugs set to fracture COPD market
10 October 2012
Top executive appointments at Boehringer and Bristol-Myers
1 October 2012
NICE final guidance backs NHS use of Boehringer Ingelheim's Actilyse
25 September 2012
Top drugmakers set up non-profit TransCelerate to speed pharma R&D
20 September 2012
NICE issues draft guidance on Boehringer's Actilyse
27 August 2012
Boehringer Ingelheim first-half 2012 sales up 6.8%
15 August 2012
Boehringer Ingelheim acquires Funxional products
24 July 2012
More news from American Diabetes Association meeting
13 June 2012
Highlights of American Diabetes Association meeting
11 June 2012
Ablynx extends Nanobody deal with Boehringer
21 March 2012
NICE recommends NHS use of Pradaxa
15 March 2012
Boehringer Ingelheim links with Xencor on MAb supply
23 February 2012
FDA approves combo diabetes drug Jentadueto and Kalydeco
1 February 2012
Added benefit of Trajenta not proven, says German agency
10 January 2012
FORMA Thera in up to $815 million deal with Boehringer
6 January 2012
COPD market to grow to more than $13.4 billion in 2020
19 December 2011
Boehringer expands in China; Lundbeckfond ups ALK-Abello stake
15 December 2011
FDA reviews Pradaxa bleeding risk
8 December 2011
EMA says bleeding risks associated with Boehringer Ingelheim’s Pradaxa can be managed
20 November 2011
UK NICE recommends Boehringer’s Pradaxa for stroke prevention
1 November 2011
Benefits of Boehringer’s Pradaxa come at high cost, study finds
20 October 2011
Boehringer Ingelheim’s Combivent Respimat Inhalation Spray OKed in USA to replace aerosol
9 October 2011
In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions
4 October 2011
Australian government U-turn on PBS listing of drugs
3 October 2011
Boehringer once-daily AIDS drug Viramune cleared in EU
21 September 2011
UK’s NICE asks for more info on Boehringer’s Pradaxa; backs Novartis’ Tasigna but not Glivec or B-MS Sprycel for leukemia
18 August 2011
Now Boehringer and Bristol-Myers in talks to join Medicines Patent Pool for HIV medicines
19 July 2011
EMA recommends Boehringer/Lilly’s Tradjenta, Novartis’ Votubia and Sigma-Tau’s Eurartesim; updates on pioglitazone
27 June 2011
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
